Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $14.3 million.

  • Eton Pharmaceuticals' Accounts Payables rose 43125.93% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 43125.93%. This contributed to the annual value of $4.2 million for FY2024, which is 12548.7% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Accounts Payables stood at $14.3 million for Q3 2025, which was up 43125.93% from $12.1 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Accounts Payables' 5-year high stood at $14.3 million during Q3 2025, with a 5-year trough of $1.1 million in Q3 2022.
  • Its 5-year average for Accounts Payables is $3.4 million, with a median of $2.1 million in 2022.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Accounts Payables crashed by 6779.71% in 2022, and later surged by 46924.52% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Accounts Payables stood at $1.8 million in 2021, then fell by 0.45% to $1.8 million in 2022, then increased by 4.64% to $1.8 million in 2023, then surged by 125.49% to $4.2 million in 2024, then surged by 242.19% to $14.3 million in 2025.
  • Its Accounts Payables stands at $14.3 million for Q3 2025, versus $12.1 million for Q2 2025 and $4.9 million for Q1 2025.